Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Integral Diagnostics Limited (IDX.AX)
AUD2.10
+0.03 (+1.45%)
AU ASX Healthcare Medical - Diagnostics & Research
Address
45 William Street 3000
Melbourne, VIC, AU
Melbourne, VIC, AU
CEO
Ian Kadish
Website
integraldiagnostics.com.au
IPO
2015-10-20
ISIN AU000000IDX2
Description
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across Australia and New Zealand. The company manages its service delivery through a network of 67 radiology clinics. Integral Diagnostics was incorporated in 2008 and maintains its primary corporate office in Melbourne, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD2.10
+0.03 (+1.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.12
Float Shares
339.27M
Free Float %
90.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.36% | +4.33% | -2.69% | -11.07% | -17.80% | -14.57% | -10.33% | -33.84% | -55.35% | +36.48% | +20.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.10
DCF (Unlevered)
18.01
+757.5%
DCF (Levered)
18.38
+775.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | -1 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.69
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+33.5% ★ Q4'25: +70.2% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+105.8% ★ Q4'25: +108.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+1.2% Q4'25: +2.0% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+5.0% Q4'25: +8.5% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+1.5% Q4'25: +5.8% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+31.3% Q4'25: +61.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×6.67× Q4'25: 3.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 11 Rev. Ana. 10 EPS Ana. |
Jun 2027 11 Rev. Ana. 10 EPS Ana. |
Jun 2028 10 Rev. Ana. 9 EPS Ana. |
Jun 2029 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
167.77M
est: 164.80M (+1.8%)
|
179.73M
est: 177.91M (+1.0%)
|
189.40M
est: 190.57M (-0.6%)
|
232.39M
est: 232.20M (+0.1%)
|
274.08M
est: 277.03M (-1.1%)
|
348.81M
est: 350.73M (-0.5%)
|
358.74M
est: 364.36M (-1.5%)
|
440.10M
est: 440.52M (-0.1%)
|
469.70M
est: 475.86M (-1.3%)
|
627.22M
est: 629.82M (-0.4%)
|
801.34M
789.68M – 817.71M
+27.2% YoY
|
851.76M
834.94M – 882.37M
+6.3% YoY
|
901.39M
900.27M – 902.52M
+5.8% YoY
|
967.00M
950.34M – 994.48M
+7.3% YoY
|
| EBITDA |
28.50M
est: 27.23M (+4.7%)
|
33.98M
est: 17.54M (+93.8%)
|
34.50M
est: 24.04M (+43.5%)
|
50.32M
est: 26.83M (+87.6%)
|
69.50M
est: 31.43M (+121.1%)
|
88.94M
est: 32.63M (+172.6%)
|
69.90M
est: 35.03M (+99.5%)
|
92.74M
est: 36.75M (+152.4%)
|
12.10M
est: 38.80M (-68.8%)
|
87.70M
est: 103.87M (-15.6%)
|
132.40M
130.48M – 135.11M
+27.5% YoY
|
140.73M
137.95M – 145.79M
+6.3% YoY
|
148.93M
148.75M – 149.12M
+5.8% YoY
|
159.77M
157.02M – 164.32M
+7.3% YoY
|
| EBIT |
19.78M
est: 11.04M (+79.2%)
|
24.15M
est: 17.53M (+37.7%)
|
24.89M
est: 21.48M (+15.9%)
|
36.81M
est: 26.83M (+37.2%)
|
43.82M
est: 42.49M (+3.1%)
|
54.02M
est: 51.85M (+4.2%)
|
33.04M
est: 55.68M (-40.6%)
|
49.00M
est: 58.40M (-16.1%)
|
-34.76M
est: 61.66M (-156.4%)
|
31.17M
est: 42.12M (-26.0%)
|
53.69M
52.91M – 54.79M
+27.5% YoY
|
57.07M
55.94M – 59.12M
+6.3% YoY
|
60.40M
60.32M – 60.47M
+5.8% YoY
|
64.79M
63.68M – 66.63M
+7.3% YoY
|
| Net Income |
11.39M
est: 30.58M (-62.8%)
|
15.48M
est: 12.14M (+27.5%)
|
15.08M
est: 16.53M (-8.8%)
|
20.98M
est: 18.30M (+14.7%)
|
23.03M
est: 25.21M (-8.6%)
|
31.27M
est: 27.44M (+14.0%)
|
14.60M
est: 29.46M (-50.4%)
|
25.04M
est: 25.04M (+0.0%)
|
-60.70M
est: -60.70M (+0.0%)
|
4.67M
est: 27.56M (-83.0%)
|
40.38M
37.28M – 43.49M
+46.5% YoY
|
45.99M
42.25M – 49.72M
+13.9% YoY
|
54.76M
47.62M – 61.91M
+19.1% YoY
|
62.04M
60.65M – 64.34M
+13.3% YoY
|
| SGA |
17.78M
est: 56.36M (-68.5%)
|
19.61M
est: 114.20M (-82.8%)
|
20.93M
est: 126.25M (-83.4%)
|
23.52M
est: 148.81M (-84.2%)
|
33.66M
est: 175.52M (-80.8%)
|
44.32M
est: 192.02M (-76.9%)
|
47.59M
est: 206.17M (-76.9%)
|
58.29M
est: 216.25M (-73.0%)
|
305.80M
est: 228.32M (+33.9%)
|
418.16M
est: 214.98M (+94.5%)
|
274.04M
270.06M – 279.64M
+27.5% YoY
|
291.29M
285.53M – 301.75M
+6.3% YoY
|
308.26M
307.88M – 308.64M
+5.8% YoY
|
330.70M
325.00M – 340.09M
+7.3% YoY
|
| EPS |
0.08
est: 0.10 (-16.7%)
|
0.11
est: 0.11 (+1.9%)
|
0.07
est: 0.12 (-39.9%)
|
0.10
est: 0.16 (-38.0%)
|
0.12
est: 0.15 (-20.4%)
|
0.16
est: 0.19 (-17.6%)
|
0.07
est: 0.12 (-43.2%)
|
0.11
est: 0.09 (+26.5%)
|
-0.26
est: 0.08 (-427.7%)
|
0.02
est: 0.09 (-83.6%)
|
0.13
0.12 – 0.14
+40.3% YoY
|
0.15
0.14 – 0.16
+16.5% YoY
|
0.17
0.15 – 0.20
+14.5% YoY
|
0.20
0.20 – 0.21
+15.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
313.92M
OE per share TTM
0.98
Owner's Yield
38.81%
Maintenance CapEx ratio
857.73%
Maint CapEx / Avg PPE
62.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 36 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - Small Companies Masters ETF MVS.AX | 1.46% | 1.80M | 0.49% |
| 2 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.26% | 231.2K | 0.55% |
| 3 | WisdomTree International SmallCap Dividend Fund DLS | 0.05% | 545.4K | 0.58% |
| 4 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.05% | 211.2K | 0.48% |
| 5 | iShares Ageing Population UCITS ETF AGED.L | 0.04% | 392.2K | 0.40% |
| 6 | Dimensional - International Small Cap Value ETF DISV | 0.04% | 1.96M | 0.42% |
| 7 | Vanguard Australian Shares Index ETF VAS.AX | 0.03% | 5.11M | 0.07% |
| 8 | BetaShares - FTSE RAFI Australia 200 ETF QOZ.AX | 0.02% | 204.7K | 0.40% |
| 9 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 1.02M | 0.06% |
| 10 | Dimensional - International Small Cap ETF DFIS | 0.02% | 1.02M | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
15.8K
Shares Outstanding
373.07M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ian Kadish | Chief Executive Officer, MD & Executive Director | 1M | — |
| Manish Mittal | Radiologist Executive Director | 837.9K | — |
| Scott Paterson | Chief Financial Officer | 694.8K | male |
| Melissa Wong | Chief People Officer | — | female |
| Robin Harle | Co-Chief Medical Officer | — | — |
| Tony Chen | Co-Chief Medical Officer | — | — |
| John Merity | Company Secretary | — | male |
| Julian Gully | Chief Information Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IDX.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
